CoChat
Sign Up
Cited by 69

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma

Zhou, Yao-Yao, Zhu, Gui-Qi, Liu, Tian, Zheng, Ji-Na, Cheng, Zhang, Zou, Tian-Tian, Braddock, Martin, Fu, Shen-Wen, Zheng, Ming-Hua·2016·Scientific Reports
DOI 10.1038/srep33743PMC PMC5027387
Open this paper in CoChat — free account

Abstract

Antidiabetic medication may modify the incidence of hepatocellular carcinoma (HCC). We aimed to compare the use of different antidiabetic strategies and the incidence of HCC. PubMed, Embase.com and Cochrane Library databases were searched up to 31 October 2015 and randomized controlled trials (RCTs), cohort studies or case-control studies were included for our analyses. A total of thirteen studies enrolling 481358 participants with 240678 HCC cases who received at least two different strategies were retrieved in this analysis. Direct comparisons showed that use of metformin (risk ratio [RR] 0.49, 95% CI 0.25–0.97) was associated with a significant risk reduction of HCC, while insulin (RR = 2.44, 95% CI 1.10- 5.56) may significantly increase the risk. Indirect evidence also suggested that insulin (RR = 2.37, 95% CI 1.21–4.75) was associated with a significantly increased risk of HCC. Additionally, metformin was effective in reducing the risk of HCC when compared with sulphonylurea (RR = 0.45, 95% CI 0.27–0.74) and insulin (RR = 0.28, 95% CI 0.17–0.47). Notably, metformin was hierarchically the best when compared with other antidiabetic therapies for the prevention of HCC. In summary, available evidence suggests that metformin was the most effective strategy to reduce HCC risk when compared with other antidiabetic interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep33743

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 6 references

Research works printed but not linked: 41

  1. El-Serag, H. B. Hepatocellular carcinoma. The New England journal of medicine 365, 1118–1127, doi: 10.1056/NEJMra1001683 (2011). · DOI · Paper page
  2. Davila, J. A., Morgan, R. O., Shaib, Y., McGlynn, K. A. & El-Serag, H. B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54, 533–539, doi: 10.1136/gut.2004.052167 (2005). · DOI
  3. El-Serag, H. B., Tran, T. & Everhart, J. E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460–468 (2004). · DOI
  4. Nicolucci, A. Epidemiological aspects of neoplasms in diabetes. Acta diabetologica 47, 87–95, doi: 10.1007/s00592-010-0187-3 (2010). · DOI
  5. Oberaigner, W. et al. Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. BMC public health 14, 1058, doi: 10.1186/1471-2458-14-1058 (2014). · DOI
  6. Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. & Thun, M. J. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. American journal of epidemiology 159, 1160–1167, doi: 10.1093/aje/kwh161 (2004). · DOI
  7. El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 4, 369–380, doi: 10.1016/j.cgh.2005.12.007 (2006). · DOI
  8. Donadon, V., Balbi, M., Casarin, P., Vario, A. & Alberti, A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World journal of gastroenterology 14, 5695–5700 (2008). · DOI
  9. Donadon, V. et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World journal of gastroenterology 15, 2506–2511 (2009). · DOI
  10. Lai, S. W. et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. The American journal of gastroenterology 107, 46–52, doi: 10.1038/ajg.2011.384 (2012). · DOI
  11. Bosetti, C. et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. The oncologist 18, 148–156, doi: 10.1634/theoncologist.2012-0302 (2013). · DOI
  12. Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606–615, doi: 10.1136/gutjnl-2011-301708 (2013). · DOI
  13. Donadon, V., Balbi, M., Mas, M. D., Casarin, P. & Zanette, G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver international: official journal of the International Association for the Study of the Liver 30, 750–758, doi: 10.1111/j.1478-3231.2010.02223.x (2010). · DOI
  14. Chang, C. H. et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 55, 1462–1472, doi: 10.1002/hep.25509 (2012). · DOI
  15. Home, P. D. et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53, 1838–1845, doi: 10.1007/s00125-010-1804-y (2010). · DOI
  16. Yu, M. C., Tong, M. J., Govindarajan, S. & Henderson, B. E. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. Journal of the National Cancer Institute 83, 1820–1826 (1991). · DOI
  17. Oliveria, S. A., Koro, C. E., Yood, M. U. & Sowell, M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2, 47–57 (2008). · DOI
  18. Hassan, M. M. et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116, 1938–1946, doi: 10.1002/cncr.24982 (2010). · DOI
  19. Kawaguchi, T. et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver international: official journal of the International Association for the Study of the Liver 30, 479–486, doi: 10.1111/j.1478-3231.2009.02191.x (2010). · DOI
  20. Nkontchou, G. et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. The Journal of clinical endocrinology and metabolism 96, 2601–2608, doi: 10.1210/jc.2010-2415 (2011). · DOI
  21. Ruiter, R. et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes care 35, 119–124, doi: 10.2337/dc11-0857 (2012). · DOI
  22. Schlesinger, S. et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 24, 2449–2455, doi: 10.1093/annonc/mdt204 (2013). · DOI
  23. Hagberg, K. W., McGlynn, K. A., Sahasrabuddhe, V. V. & Jick, S. Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. British journal of cancer 111, 1710–1717, doi: 10.1038/bjc.2014.447 (2014). · DOI
  24. Bosetti, C. et al. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases. Pharmacoepidemiology and drug safety 24, 771–778, doi: 10.1002/pds.3801 (2015). · DOI
  25. Miele, L. et al. Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Gastroenterology research and practice 2015, 570356, doi: 10.1155/2015/570356 (2015). · DOI
  26. Chang, C. H., Lin, J. W., Wu, L. C., Lai, M. S. & Chuang, L. M. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism 97, E1170–E1175, doi: 10.1210/jc.2012-1162 (2012). · DOI
  27. Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. The American journal of gastroenterology 108, 881–891, quiz 892, doi: 10.1038/ajg.2013.5 (2013). · DOI
  28. Decensi, A. et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer prevention research 3, 1451–1461, doi: 10.1158/1940-6207.CAPR-10-0157 (2010). · DOI · Paper page
  29. Harris, K. & Smith, L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. The Annals of pharmacotherapy 47, 1348–1352, doi: 10.1177/1060028013503108 (2013). · DOI
  30. Zhang, H., Gao, C., Fang, L., Zhao, H. C. & Yao, S. K. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scandinavian journal of gastroenterology 48, 78–87, doi: 10.3109/00365521.2012.719926 (2013). · DOI
  31. Pasello, G., Urso, L., Conte, P. & Favaretto, A. Effects of sulfonylureas on tumor growth: a review of the literature. The oncologist 18, 1118–1125, doi: 10.1634/theoncologist.2013-0177 (2013). · DOI
  32. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L. & Vigneri, R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine reviews 30, 586–623, doi: 10.1210/er.2008-0047 (2009). · DOI
  33. Pollak, M. N., Schernhammer, E. S. & Hankinson, S. E. Insulin-like growth factors and neoplasia. Nature reviews. Cancer 4, 505–518, doi: 10.1038/nrc1387 (2004). · DOI
  34. Moore, M. A., Park, C. B. & Tsuda, H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation 7, 89–107 (1998). · DOI
  35. Jalving, M. et al. Metformin: taking away the candy for cancer? European journal of cancer 46, 2369–2380, doi: 10.1016/j.ejca.2010.06.012 (2010). · DOI
  36. Gallagher, E. J. & LeRoith, D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Annals of the New York Academy of Sciences 1243, 54–68, doi: 10.1111/j.1749-6632.2011.06285.x (2011). · DOI
  37. Dowling, R. J., Goodwin, P. J. & Stambolic, V. Understanding the benefit of metformin use in cancer treatment. BMC medicine 9, 33, doi: 10.1186/1741-7015-9-33 (2011). · DOI
  38. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of clinical investigation 108, 1167–1174, doi: 10.1172/JCI13505 (2001). · DOI · Paper page
  39. Okumura, T. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. Journal of gastroenterology 45, 1097–1102, doi: 10.1007/s00535-010-0310-9 (2010). · DOI
  40. Wu C. W., Farrell G. C. & Yu J. Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma. Journal of gastroenterology and hepatology 27, 1665–1669, doi: 10.1111/j.1440-1746.2012.07213.x (2012). · DOI
  41. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of clinical epidemiology 62, 1006–1012, doi: 10.1016/j.jclinepi.2009.06.005 (2009). · DOI · Paper page

Cited by

Sorted by citations

See all 69

Metadata

Authors
Zhou, Y.-Y., Zhu, G.-Q., Liu, T., Zheng, J.-N., Cheng, Z., Zou, T.-T., Braddock, M., Fu, S.-W., & Zheng, M.-H.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2016-09-19
Volume
6
Issue
1
ISSN
2045-2322
DOI
10.1038/srep33743
PMC
PMC5027387
Cited by
69
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review